TY - JOUR
T1 - ADAMTS-13 and bleeding phenotype in von Willebrand disease
AU - Boender, Johan
AU - Nederlof, Angelique
AU - Meijer, Karina
AU - Mauser-Bunschoten, Evelien P.
AU - Cnossen, Marjon H.
AU - Fijnvandraat, Karin
AU - van der Bom, Johanna G.
AU - de Meris, Joke
AU - Laros-van Gorkom, Britta A.P.
AU - van Galen, Karin P.M.
AU - Eikenboom, Jeroen
AU - de Maat, Moniek P.M.
AU - Leebeek, Frank W.G.
AU - Coppens, M.
AU - Nieuwenhuizen, L.
AU - Tamminga, R. Y.J.
AU - Ypma, P. F.
AU - Smiers, F. J.W.
AU - Beckers, E.
AU - Brons, P.
AU - Atiq, F.
N1 - Funding Information:
This project was supported by a 2017 EAHAD research grant. The WiN study is supported by research funding from the Dutch Hemophilia Foundation (Stichting Haemophilia) and CSL Behring (unrestricted grant). A complete list of the members of the WiN study appears in the appendix.
Funding Information:
This project was supported by a 2017 EAHAD research grant. The WiN study is supported by research funding from the Dutch Hemophilia Foundation (Stichting Haemophilia) and CSL Behring (unrestricted grant). A complete list of the members of the WiN study appears in the appendix.
Publisher Copyright:
© 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.
PY - 2020/11
Y1 - 2020/11
N2 - Background: The bleeding phenotype of von Willebrand disease (VWD) varies highly between patients and can only partly be explained by von Willebrand factor (VWF) parameters. By cleaving large VWF multimers into smaller, less active multimers, ADAMTS-13 is an important regulator of VWF activity. However, it is unknown what the role of ADAMTS-13 is in individuals with VWD. Objectives: We therefore studied how ADAMTS-13 activity is associated with the laboratory and bleeding phenotype in individuals with VWD. Methods: We measured ADAMTS-13 activity using the fluorescence resonance energy transfer substrate VWF 73 assay in 638 individuals with VWD in the nationwide cross-sectional Willebrand in the Netherlands study and in 36 healthy controls. The bleeding phenotype was assessed using the Tosetto bleeding score. Results: ADAMTS-13 activity was similar in individuals with VWD (109% ± 20.6%) and controls (110% ± 19.7%). ADAMTS-13 activity was higher in individuals with VWD with type 3 than those with type 1 (mean difference, 11.8%; 95% confidence interval [CI], 2.9%-20.8%) or type 2 (mean difference, 16.1%; 95% CI, 7.1%-25.1%). ADAMTS-13 activity was not associated with the Tosetto bleeding score (0.1 Tosetto bleeding score increase per 10% ADAMTS-13 increase, 95% CI, −0.2 to 0.3). Furthermore, ADAMTS-13 activity did not differ between individuals with and without a bleeding event during the year preceding blood sampling (mean difference, 1.4%; 95% CI, −2.1% to 4.9%). Conclusion: ADAMTS-13 activity was highest in individuals with type 3 VWD, but it had only minor associations with VWF parameters. ADAMTS-13 activity does not influence the bleeding phenotype in individuals with VWD.
AB - Background: The bleeding phenotype of von Willebrand disease (VWD) varies highly between patients and can only partly be explained by von Willebrand factor (VWF) parameters. By cleaving large VWF multimers into smaller, less active multimers, ADAMTS-13 is an important regulator of VWF activity. However, it is unknown what the role of ADAMTS-13 is in individuals with VWD. Objectives: We therefore studied how ADAMTS-13 activity is associated with the laboratory and bleeding phenotype in individuals with VWD. Methods: We measured ADAMTS-13 activity using the fluorescence resonance energy transfer substrate VWF 73 assay in 638 individuals with VWD in the nationwide cross-sectional Willebrand in the Netherlands study and in 36 healthy controls. The bleeding phenotype was assessed using the Tosetto bleeding score. Results: ADAMTS-13 activity was similar in individuals with VWD (109% ± 20.6%) and controls (110% ± 19.7%). ADAMTS-13 activity was higher in individuals with VWD with type 3 than those with type 1 (mean difference, 11.8%; 95% confidence interval [CI], 2.9%-20.8%) or type 2 (mean difference, 16.1%; 95% CI, 7.1%-25.1%). ADAMTS-13 activity was not associated with the Tosetto bleeding score (0.1 Tosetto bleeding score increase per 10% ADAMTS-13 increase, 95% CI, −0.2 to 0.3). Furthermore, ADAMTS-13 activity did not differ between individuals with and without a bleeding event during the year preceding blood sampling (mean difference, 1.4%; 95% CI, −2.1% to 4.9%). Conclusion: ADAMTS-13 activity was highest in individuals with type 3 VWD, but it had only minor associations with VWF parameters. ADAMTS-13 activity does not influence the bleeding phenotype in individuals with VWD.
KW - ADAMTS-13 protein
KW - blood coagulation disorders
KW - human
KW - von Willebrand diseases
KW - von Willebrand factor
UR - http://www.scopus.com/inward/record.url?scp=85096802336&partnerID=8YFLogxK
U2 - 10.1002/rth2.12442
DO - 10.1002/rth2.12442
M3 - Article
AN - SCOPUS:85096802336
SN - 2475-0379
VL - 4
SP - 1331
EP - 1339
JO - Research and practice in thrombosis and haemostasis
JF - Research and practice in thrombosis and haemostasis
IS - 8
ER -